Journey Medical Corporation
NASDAQ Capital MarketTotal Valuation
Journey Medical Corporation carries a market capitalization of 216.32M, placing it among publicly traded companies globally. Its enterprise value stands at 195.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 216.32M |
| Enterprise Value | 195.71M |
Share Statistics
Journey Medical Corporation currently has 27.66M shares outstanding.
| Shares Outstanding | 27.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.76, and the price-to-book ratio stands at 6.10.
| PE Ratio | N/A |
| PS Ratio | 2.76 |
| PB Ratio | 6.10 |
| P/TBV Ratio | 29.65 |
| P/FCF Ratio | -25.12 |
| P/OCF Ratio | -25.12 |
Enterprise Valuation
On an enterprise value basis, Journey Medical Corporation trades at an EV/EBITDA multiple of 149.74 and an EV/FCF ratio of 6.90.
| EV / Sales | 2.87 |
| EV / EBITDA | 149.74 |
| EV / EBIT | N/A |
| EV / FCF | 6.90 |
Financial Position
Journey Medical Corporation maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.53, indicating elevated leverage, while an interest coverage ratio of 0.36 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.59 |
| Quick Ratio | 1.35 |
| Debt / Equity | 79.53 |
| Debt / EBITDA | 19.54 |
| Interest Coverage | 0.36 |
Financial Efficiency
| Return on Equity (ROE) | -23.77 |
| Return on Assets (ROA) | -6.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.24 |
Taxes
| Income Tax | 15,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Journey Medical Corporation's stock has gained approximately 12.12553% over the past 52 weeks. The 50-day moving average sits at 6.94, while the 200-day moving average is 6.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | 12.12553% |
| 50-Day Moving Average | 6.94 |
| 200-Day Moving Average | 6.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Journey Medical Corporation generated 68.18M in revenue and converted that into -6.10M in net income, yielding earnings per share of -0.23. EBITDA reached 1.31M, while operating income came in at -3.01M.
| Revenue | 68.18M |
| Gross Profit | 44.63M |
| Operating Income | -3.01M |
| Pretax Income | -6.09M |
| Net Income | -6.10M |
| EBITDA | 1.31M |
| EBIT | -3.01M |
| Earnings Per Share (EPS) | -0.23 |
Balance Sheet
Journey Medical Corporation holds 25.64M in cash and equivalents against 25.54M in total debt, resulting in a net debt position of -171,000.00. Total book value stands at 32.11M, with working capital of 27.01M providing operational flexibility.
| Cash & Cash Equivalents | 25.64M |
| Total Debt | 25.54M |
| Net Debt | -171,000.00 |
| Equity (Book Value) | 32.11M |
| Book Value Per Share | 1.16 |
| Working Capital | 27.01M |
Cash Flow
Journey Medical Corporation produced -7.49M in operating cash flow over the past twelve months.
| Operating Cash Flow | -7.49M |
| Capital Expenditures | N/A |
| Free Cash Flow | -7.49M |
| FCF Per Share | -0.28 |
Margins
Journey Medical Corporation operates with a gross margin of 65.45, reflecting its pricing power and cost economics. The operating margin of -4.41 and net profit margin of -8.95 provide insight into operational efficiency.
| Gross Margin | 65.45 |
| Operating Margin | -4.41 |
| Pretax Margin | -8.93 |
| Profit Margin | -8.95 |
| EBITDA Margin | 1.92 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.56 |
| FCF Yield | -3.98 |
Scores
Journey Medical Corporation posts an Altman Z-Score of 1.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.08 |